Treatment with palbociclib and tislelizumab for CDKN2A-mutated and PD-L1-positive advanced intrahepatic cholangiocarcinoma: a case report and literature review. The gene discussed is CDKN2A; the disease is intrahepatic cholangiocarcinoma.